The Vaccine Group starts work on COVID-19 animal vaccine, makes strong progress with technology
The Vaccine Group is today announcing it has made significant progress towards developing its novel vaccine platform technology
Read moreThe Vaccine Group video to The Vaccine Group starts work on COVID-19 animal vaccine
The Vaccine Group is to ‘imminently’ start trials of its coronavirus vaccine in animals.
View hereElute Intelligence supports scientists researching COVID-19
Elute Intelligence Holdings has launched a dedicated free-to-use online COVID-19 Document Reader to help scientists worldwide tackling the disease to find vital research more rapidly
Read moreFrontier IP Group’s Neil Crabb reports back on ‘solid’ portfolio growth and developments
Neil Crabb caught up with Proactive London’s Andrew Scott to update on recent developments with its portfolio companies
View hereCambridge Raman Imaging wins €140,000 EU Graphene Flagship funding
Cambridge Raman Imaging Limited has been awarded €140,000 by the European Union’s Graphene Flagship to accelerate development of its innovative graphene-enabled scanning Raman microscope
Read moreFrontier IP raises stake in Celerum to 33.8 per cent
Frontier IP Group has raised its equity stake in portfolio company Celerum Limited from 10 per cent to 33.8 per cent
Read moreExscientia: worlds first trials of new drug candidate created by artificial intelligence
Sumitomo Dainippon Pharma Co., Ltd. and Exscientia Ltd. announce that a phase I clinical study of DSP-1181, that was created using Artificial Intelligence, has been initiated in Japan for the treatment of obsessive-compulsive disorder as an initial indication.
Read moreThe Vaccine Group raises £680,000 through initial equity fund raise
The Vaccine Group (TVG) has raised £680,000 through its first equity funding round.
Read moreFieldwork raises £298,000 in first equity funding round
Fieldwork Robotics has raised £298,000 through an initial equity funding round.
Read moreBayer and Exscientia collaborate to use AI in cardiovascular and oncology drug discovery
Exscientia announced today that it has entered a collaboration with Bayer AG that aims to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Read more